201 related articles for article (PubMed ID: 12588772)
1. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Marx N; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Scharnagl H; Hombach V; Koenig W
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):283-8. PubMed ID: 12588772
[TBL] [Abstract][Full Text] [Related]
2. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Marx N; Imhof A; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Maerz W; Hombach V; Koenig W
Circulation; 2003 Apr; 107(15):1954-7. PubMed ID: 12695287
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Haffner SM; Greenberg AS; Weston WM; Chen H; Williams K; Freed MI
Circulation; 2002 Aug; 106(6):679-84. PubMed ID: 12163427
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.
Hetzel M; Walcher D; Grüb M; Bach H; Hombach V; Marx N
Thorax; 2003 Sep; 58(9):778-83. PubMed ID: 12947137
[TBL] [Abstract][Full Text] [Related]
5. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
6. [Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients].
Huang Z; Lei MX; Liu L; Tang QB
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):367-72. PubMed ID: 16859126
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
9. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Yang WS; Jeng CY; Wu TJ; Tanaka S; Funahashi T; Matsuzawa Y; Wang JP; Chen CL; Tai TY; Chuang LM
Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Marfella R; D'Amico M; Esposito K; Baldi A; Di Filippo C; Siniscalchi M; Sasso FC; Portoghese M; Cirillo F; Cacciapuoti F; Carbonara O; Crescenzi B; Baldi F; Ceriello A; Nicoletti GF; D'Andrea F; Verza M; Coppola L; Rossi F; Giugliano D
Diabetes; 2006 Mar; 55(3):622-32. PubMed ID: 16505224
[TBL] [Abstract][Full Text] [Related]
11. [Rosiglitazone (BRL-49653)].
Kameda N; Okuya S; Oka Y
Nihon Rinsho; 2000 Feb; 58(2):401-4. PubMed ID: 10707565
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a potent antiinflammatory effect of rosiglitazone.
Mohanty P; Aljada A; Ghanim H; Hofmeyer D; Tripathy D; Syed T; Al-Haddad W; Dhindsa S; Dandona P
J Clin Endocrinol Metab; 2004 Jun; 89(6):2728-35. PubMed ID: 15181049
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Khandoudi N; Delerive P; Berrebi-Bertrand I; Buckingham RE; Staels B; Bril A
Diabetes; 2002 May; 51(5):1507-14. PubMed ID: 11978649
[TBL] [Abstract][Full Text] [Related]
18. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Doležalová R; Haluzík MM; Bošanská L; Lacinová Z; Kasalová Z; Stulc T; Haluzík M
Physiol Res; 2007; 56(6):741-748. PubMed ID: 17087601
[TBL] [Abstract][Full Text] [Related]
19. [Rosiglitazone(BRL-49653)].
Yonezawa N; Oka Y
Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
